BAFNAPH — Bafna Pharmaceuticals Balance Sheet
0.000.00%
- IN₹1.90bn
- IN₹2.08bn
- IN₹1.53bn
- 29
- 27
- 50
- 24
Annual balance sheet for Bafna Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
C2020 March 31st | 2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 84.8 | 18 | 1.73 | 78.1 | 21 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 60.3 | 95.6 | 155 | 559 | 615 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 359 | 497 | 509 | 873 | 945 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 352 | 368 | 388 | 402 | 507 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 711 | 865 | 901 | 1,296 | 1,477 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 171 | 243 | 220 | 465 | 541 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 201 | 297 | 282 | 561 | 668 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 509 | 568 | 620 | 735 | 808 |
Total Liabilities & Shareholders' Equity | 711 | 865 | 901 | 1,296 | 1,477 |
Total Common Shares Outstanding |